雅培Abbott Laboratories （ABT）2025年第四季度及全年业绩报告（英文版）「NYSE」（20页）.pdf

1、News ReleaseAbbott Reports Fourth-Quarter and Full-Year 2025 Results;Issues 2026 Financial OutlookFourth-quarter GAAP diluted EPS of$1.01;adjusted diluted EPS of$1.50 reflects growth of 12percentFull-year 2025 GAAP diluted EPS of$3.72;adjusted diluted EPS of$5.15 reflects growth of 10percentAbbott p

2、rojects full-year 2026 organic sales growth to be in the range of 6.5%to 7.5%Abbott projects full-year 2026 adjusted diluted EPS of$5.55 to$5.80,which reflects 10percent growth at the midpointABBOTT PARK,Ill.,Jan.22,2026 Abbott today announced financial results for the fourth quarter ended Dec.31,20

3、25.Fourth-quarter sales increased 4.4 percent on a reported basis,3.0 percent on an organic basis,or 3.8 percent when excluding COVID-19 testing-related sales1.Fourth-quarter GAAP diluted EPS of$1.01 and adjusted diluted EPS of$1.50,which excludesspecified items and reflects growth of 12 percent.Ful

4、l-year 2025 sales of$44.3 billion increased 5.7 percent on a reported basis,5.5 percent on anorganic basis,or 6.7 percent when excluding COVID-19 testing-related sales2.Full-year 2025 GAAP diluted EPS of$3.72 and adjusted diluted EPS of$5.15,which excludesspecified items and reflects growth of 10 pe

5、rcent.Abbott projects full-year 2026 organic sales growth to be in the range of 6.5%to 7.5%.Abbott projects full-year 2026 adjusted diluted EPS of$5.55 to$5.80,which reflects growth of10 percent at the midpoint.In November,Abbott announced an agreement to acquire Exact Sciences,a move that willposit

6、ion the company to enter and lead in the fast-growing cancer diagnostics market.Abbottcontinues to expect the transaction to close in the second quarter of 2026.Abbott expanded its leadership in Electrophysiology with two significant regulatory approvals:In December,Abbott announced U.S.Food and Dru